NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.

NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Jul 01; 121(13):2156-63.

View in: PubMed

subject areas

Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Bevacizumab
Chemoradiotherapy, Adjuvant
Chemoradiotherapy, Adjuvant
Cisplatin
Cisplatin
Disease-Free Survival
Disease-Free Survival
Endometrial Neoplasms
Endometrial Neoplasms
Female
Female
Humans
Humans
Hysterectomy
Hysterectomy
Lymph Node Excision
Lymph Node Excision
Middle Aged
Middle Aged
Paclitaxel
Paclitaxel
Postoperative Period
Postoperative Period
Radiotherapy, Intensity-Modulated
Radiotherapy, Intensity-Modulated

authors with profiles

Robert S Mannel